Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer.
Ravi P, Freeman D, Thomas J, Ravi A, Mantia C, McGregor BA, Berchuck JE, Epstein I, Budde P, Ahangarian Abhari B, Rupieper E, Gajewski J, Schubert AS, Kilian AL, Bräutigam M, Zucht HD, Sonpavde G. Ravi P, et al. Among authors: mantia c. J Immunother Cancer. 2024 Feb 2;12(2):e008215. doi: 10.1136/jitc-2023-008215. J Immunother Cancer. 2024. PMID: 38309723 Free PMC article.
Longitudinal Evaluation of Circulating Tumor DNA Using Sensitive Amplicon-Based Next-Generation Sequencing to Identify Resistance Mechanisms to Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma.
Ravi P, Ravi A, Riaz IB, Freeman D, Curran C, Mantia C, McGregor BA, Kilbridge KL, Pan CX, Pek M, Choudhury Y, Tan MH, Sonpavde GP. Ravi P, et al. Among authors: mantia c. Oncologist. 2022 May 6;27(5):e406-e409. doi: 10.1093/oncolo/oyac037. Oncologist. 2022. PMID: 35294031 Free PMC article.
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
McGregor BA, Sonpavde GP, Kwak L, Regan MM, Gao X, Hvidsten H, Mantia CM, Wei XX, Berchuck JE, Berg SA, Ravi PK, Michaelson MD, Choueiri TK, Bellmunt J. McGregor BA, et al. Among authors: mantia cm. Ann Oncol. 2024 Jan;35(1):91-97. doi: 10.1016/j.annonc.2023.09.3114. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871703 Clinical Trial.
Editorial Comment.
Mantia CM, Sonpavde GP. Mantia CM, et al. J Urol. 2021 Aug;206(2):250-251. doi: 10.1097/JU.0000000000001768.01. Epub 2021 May 4. J Urol. 2021. PMID: 33940928 No abstract available.
Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma.
Tripathi A, Lin E, Xie W, Flaifel A, Steinharter JA, Stern Gatof EN, Bouchard G, Fleischer JH, Martinez-Chanza N, Gray C, Mantia C, Thompson L, Wei XX, Giannakis M, McGregor BA, Choueiri TK, Agarwal N, McDermott DF, Signoretti S, Harshman LC. Tripathi A, et al. Among authors: mantia c. J Immunother Cancer. 2020 Nov;8(2):e001467. doi: 10.1136/jitc-2020-001467. J Immunother Cancer. 2020. PMID: 33177176 Free PMC article.
An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer.
Montazeri K, Dranitsaris G, Thomas JD, Curran C, Preston MA, Steele GS, Kilbridge KL, Mantia C, Ravi P, McGregor BA, Mossanen M, Sonpavde G. Montazeri K, et al. Among authors: mantia c. Urol Oncol. 2021 Dec;39(12):834.e1-834.e7. doi: 10.1016/j.urolonc.2021.04.032. Epub 2021 Jun 20. Urol Oncol. 2021. PMID: 34162500
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067.
Regan MM, Mantia CM, Werner L, Tarhini AA, Larkin J, Stephen Hodi F, Wolchok J, Postow MA, Stwalley B, Moshyk A, Ritchings C, Re S, van Dijck W, McDermott DF, Atkins MB. Regan MM, et al. Among authors: mantia cm. J Immunother Cancer. 2021 Nov;9(11):e003743. doi: 10.1136/jitc-2021-003743. J Immunother Cancer. 2021. PMID: 34799400 Free PMC article.
39 results